“Chump claimed on iHub the company intends to re
Post# of 148391
(Total Views: 1033)
Posted On: 06/30/2020 6:30:13 PM
Re: Evil Rabbit #40214
“Chump claimed on iHub the company intends to refute the Citron article point-by-point.”
And?
If this is true, CYDY is most likely going to pay another stock promotion company to write the article. That’s pure amateur hour. We’ve seen in the past that the majority of these paid articles in support of CYDY are poorly written, poorly researched and result in ZERO. If the article could bring back $4 of PPS for those who bought in the $6-10 range, that would be great, but paid advertising just doesn’t do that. Refer to all the proactive videos from the .60 down to the .20 range. Great for longs, but not for recovering the SP.;
Again, Citron is a small player in the larger business of shorting stocks. We saw this coming last week, the question was when. Other posters were mentioning yesterday how overbought the stock was, another hint the top was near.
My advice to CYDY: stay the current path of keeping silent, release material events, and continue to fill the COVID, cancer, and NASH trials (maybe Mono). No more Proactive videos for now.
And?
If this is true, CYDY is most likely going to pay another stock promotion company to write the article. That’s pure amateur hour. We’ve seen in the past that the majority of these paid articles in support of CYDY are poorly written, poorly researched and result in ZERO. If the article could bring back $4 of PPS for those who bought in the $6-10 range, that would be great, but paid advertising just doesn’t do that. Refer to all the proactive videos from the .60 down to the .20 range. Great for longs, but not for recovering the SP.;
Again, Citron is a small player in the larger business of shorting stocks. We saw this coming last week, the question was when. Other posters were mentioning yesterday how overbought the stock was, another hint the top was near.
My advice to CYDY: stay the current path of keeping silent, release material events, and continue to fill the COVID, cancer, and NASH trials (maybe Mono). No more Proactive videos for now.
(6)
(1)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼